Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays.

BACKGROUND CYP2D6 is involved in the oxidative metabolism of approximately 20% of all clinically used medications. Genotyping cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), is a challenge because of the high complexity of the locus. METHODS Twenty-nine CYP2D6 sequence variants were genotyped in 50 deidentified patient samples and 29 Coriell DNAs by Invader assay, and results were compared with Infiniti assay and Sanger sequencing. To determine CYP2D6 copy number, 3 TaqMan real-time hydrolysis probes were used and results were compared with long-range PCR. Discrimination of the duplicated alleles was done on 17 DNA samples with 3 copies of CYP2D6 by long-range PCR followed by Invader genotyping and single nucleotide extension for the comparison. RESULTS Complete concordance was observed for all samples between platforms except for 2 samples due to the lack of the *45 allele in the Infiniti panel. Reproducibility with the Invader assay and TaqMan copy number was 100%. Analytical sensitivity using DNA with 2 copies was determined to be 10 ng DNA for the Invader assay and 1 ng/μL DNA for the TaqMan assay, respectively. Complete concordance and reproducibility were observed for duplicated allele discrimination with the exception of 1 sample, determined to be *29/*43X2 by the Invader test and *1X2/*29 by the Infiniti method, which did not test for *43. CONCLUSIONS This validation study showed that Invader and TaqMan assay combined panel provides an attractive, valid, highly accurate, and reproducible approach for CYP2D6 genotyping for clinical implementation.

[1]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.

[2]  Yusuke Nakamura,et al.  Establishment of CYP2D6 Reference Samples by Multiple Validated Genotyping Platforms , 2014, The Pharmacogenomics Journal.

[3]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.

[4]  Soma Das,et al.  Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project” , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[5]  Yusuke Nakamura,et al.  Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. , 2013, Pharmacogenomics.

[6]  Y. Daali,et al.  Applications of CYP450 Testing in the Clinical Setting , 2013, Molecular Diagnosis & Therapy.

[7]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[8]  Victoria M. Pratt,et al.  Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants , 2010, Front. Pharmacol..

[9]  Yusuke Nakamura,et al.  Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays , 2010, Pharmacogenetics and genomics.

[10]  U. Fuhr,et al.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. , 2010, Pharmacogenomics.

[11]  Yusuke Nakamura,et al.  CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. , 2009, Clinical chemistry.

[12]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[13]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[14]  E. Reed,et al.  Clinical Utility of Microarrays: Current Status, Existing Challenges and Future Outlook , 2008, Current genomics.

[15]  E. Lyon,et al.  Simultaneous amplification, detection, and analysis of common mutations in the galactose-1-phosphate uridyl transferase gene. , 2007, The Journal of molecular diagnostics : JMD.

[16]  I Zineh,et al.  Cytochrome P4502D6 (CYP2D6) Gene Locus Heterogeneity: Characterization of Gene Duplication Events , 2007, Clinical pharmacology and therapeutics.

[17]  J. Schellens,et al.  Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6 , 2007, Drug metabolism reviews.

[18]  K. Neville,et al.  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.

[19]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[20]  V. Lyamichev,et al.  Invader assay for SNP genotyping. , 2003, Methods in molecular biology.

[21]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  M. Ingelman-Sundberg,et al.  Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. , 1999, Gene.

[23]  J. Weide,et al.  Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. , 1998, Clinical chemistry.

[24]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[25]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[26]  F. Guengerich,et al.  Polymorphism of human cytochrome P-450. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.